Arcutis’ ZORYVE Now in Preferred Position on National Formularies for CVS Caremark

ZORYVE is a once-daily, steroid-free phosphodiesterase-4 (PDE4) inhibitor cream.

Arcutis Biotherapeutics, Inc.’s ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on national formularies for CVS Caremark.

ZORYVE is covered for individuals with plaque psoriasis and a prior history of use of a topical steroid, although no prior steroid therapy is required for individuals with plaque psoriasis in sensitive skin areas.

“This is the largest U.S. pharmacy benefit manager, and the third to include ZORYVE on its national formularies since we launched less than a year ago. We have now unlocked broad high-quality access for a total of 131 million commercially insured patients, representing 80% of covered lives in the United States. Notably, in line with our access goals, more than 90% of the 130 million covered commercial patients have access to ZORYVE without a prior authorization,” says Frank Watanabe, President and CEO of Arcutis, in a news release. “The placement of ZORYVE in a preferred tier position aligns with our focus on ensuring affordable access to ZORYVE so that adults and adolescents with plaque psoriasis can benefit from our effective and well-tolerated therapy.” 

In addition to working with payers, the company is committed to providing affordable access to ZORYVE through responsible pricing, ZORYVE Direct, a patient access support and saving program*, and the Arcutis Cares patient assistance program, which provides ZORYVE at no cost for financially eligible patients who are uninsured or underinsured.